Testing neladalkib for untreated ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread and cannot be treated with surgery or radiation alone.
- Your tumor has a specific ALK gene change (rearrangement) confirmed by a tissue or blood test.
- You have not had any prior treatment for advanced lung cancer, except for certain chemotherapy before surgery or radiation if it was more than 12 months ago.
- You have at least one tumor that can be measured on scans (like a CT scan).
- You are willing to provide a sample of your tumor tissue before starting the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program lets people with advanced ALK-positive cancer (like lung cancer) who have run out of standard options try an investigational drug called neladalkib through an expanded access program, not a clinical trial.
This study tests a new pill (SY-3505) compared to the standard first treatment (crizotinib) for people with ALK-positive advanced lung cancer that hasn't been treated yet. If you qualify, you'd be randomly assigned to one of these two oral medicines, and the study will see which one works better.
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This trial tests combining the targeted pill alectinib with chemotherapy before the main treatment for stage III ALK-positive lung cancer that can't be removed surgically. The goal is to see if this combo shrinks the tumor and improves outcomes.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.